NICE recommends Ebglyss for atopic dermatitis patients
Almirall’s Ebglyss is predicted to hit blockbuster status in two years in the crowded atopic dermatitis market.
11 July 2024
11 July 2024
Almirall’s Ebglyss is predicted to hit blockbuster status in two years in the crowded atopic dermatitis market.
Lomecel-B is being investigated as a treatment for hypoplastic left heart syndrome, and ageing-related frailty, in addition to Alzheimer’s disease.
The FDA has approved the once-daily topical cream for mild to moderate atopic dermatitis in patients aged six and older.
The aberrant expression of MYB is a common factor in cancers such as ACC, AML and CRC.
According to a recent survey by biopharma solutions provider Cytiva, resilience remains a critical priority for industry leaders.
Trials assessed the drug’s safety and efficacy, with one Phase I/IIa trial conducted in the country and an external Phase I trial.
Leqembi is intended for patients with mild cognitive impairment or at the mild dementia stage of the disease.
PharmassêtX's green tea component, EGCG, is being developed as a high-purity drug for treating a rare form of IBD.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.